SGLT2 inhibitors reduce all-cause mortality
- 1 May 2021
- journal article
- editorial
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 174 (5), JC52-JC53
- https://doi.org/10.7326/acpj202105180-052
Abstract
Source Citation Silverii GA, Monami M, Mannucci E. Sodium–glucose co-transporter-2 inhibitors and all-cause mortality: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2021;23:... Clinical Impact Ratings GIM/FP/GP: 6 out of 7 Endocrinology: 5 out of 7This publication has 7 references indexed in Scilit:
- Dapagliflozin in Patients with Chronic Kidney DiseaseThe New England Journal of Medicine, 2020
- The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristicsNephrology Dialysis Transplantation, 2020
- SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysisThe Lancet Diabetes & Endocrinology, 2019
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyThe New England Journal of Medicine, 2019
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trialThe Lancet Diabetes & Endocrinology, 2019
- Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney FunctionJournal of the American College of Cardiology, 2018
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trialsThe Lancet Diabetes & Endocrinology, 2018